- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Bharat Biotech Covaxin booster dose broadens immunity against Delta, Omicron variants: ICMR study
New Delhi: The administration of Covaxin as a booster dose enhances vaccine effectiveness against COVID-19's Delta variant and gives protection against Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech has found.
The protective efficacy of Bharat Biotech's Covaxin following two and three-dose immunisations against the Delta variant and the efficacy of the Covaxin against Omicron variants were studied in a Syrian hamster model (animal model to study human-associated diseases), it said.
The antibody response, clinical observations, viral load reduction and lung disease severity after virus challenge were observed, it added.
The findings of the study have been published on Tuesday on bioRxiv, a pre-print server and have not been peer reviewed.
"In the Delta infection study, where we compared the protective response between the two and three-dose regimens, we could observe the advantage of the booster dose vaccination in the protection. Although the neutralising antibody levels were comparable among the groups, lung disease severity was found more reduced after the three dose vaccination.
"The virus shedding and viral organ load were considerably reduced in both the two dose and three-dose immunised animals indicating the vaccine efficacy against Delta variant," the study by Indian Council of Medical Research and Bharat Biotech said.
In the second study in which the protective response was assessed against Omicron variants i.e. BA.1 and BA.2, following three-dose vaccinations, lesser virus shedding, lung viral load and lung disease severity were observed in the immunised groups in comparison to the placebo groups.
"The evidence from the present study shows that Covaxin booster immunisation tends to broaden the protective immune response and reduces disease severity against the Delta and Omicron variant infection," it further said.
Read also: Bharat Biotech Covaxin to be recognized in Germany for travel from June 1
covaxinbharat biotechbharat biotech newscovid19coronaviruscoronavirus vaccinedeltaomicronBA.1.1BA.2ICMR
Source : PTIRuchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story